EMAIL DETAILS

H:
I hope you had a fruitful trip to Como. I would like you to join me for a dinner on 4/16 with the CEO and COB of Difusion Technologies
( www.difusiontech.com)
I was introduced to this company by a friend of mine who is one of the scientific advisors - Dr. Dan George. Management will be in DC 4/16-4/18 to further discussions with the FDA regarding their 510K application and approval.
PR

Sent from my iPhone

Begin forwarded message:

> From: "derrick" <derrick@difusiontech.com>
> Date: April 6, 2014 at 9:39:38 AM EDT
> To: "'Paul'" <perowan@gmail.com>
> Subject: FW: Leerink Partners
>
> FYI – keeping Johnson & Johnson warm and honest…
>
> Depuy Synthes is J&J’s orthopedic division.
>
> If we do our deal Leerink goes on the back burner.
>
> From: Kang.Charles@synthes.com [mailto:Kang.Charles@synthes.com]
> Sent: Sunday, April 06, 2014 8:36 AM
> To: derrick@difusiontech.com; Buechter.Doug@synthes.com
> Subject: RE: Leerink Partners
>
> Thanks Derrick. We would be happy to talk with Lance.
>
> Charlie
>
> Charlie Kang
> Director Business Development
> DePuy Synthes
> 484-356-9551
> kang.charles@synthes.com
> From: derrick [mailto:derrick@difusiontech.com]
> Sent: Sunday, April 06, 2014 9:34 AM
> To: Buechter, Doug - United States, West Chester; Kang, Charles - United States, West Chester
> Subject: Leerink Partners
> Importance: High
>
> Doug and Charlie,
>
> Due to heavy interest from multiple other potential partners our Board has authorized the engagement of Lance Alstodt at Leerink Partners to manage that process on behalf of Difusion. Our De Novo application remains on track and we expect to close our deal upon FDA clearance. Should you have continued interest Lance will be your point of contact.
>
> Derrick W. Johns
> Founder & CEO
> www.difusiontech.com
>
>
> Cry ‘Havoc,’ and let slip the dogs of war;
> -CleanFuze European Approval-CE Mark 12-20-2013
>
> (512) 284-3338 (m)
> =2